Astellas Pharma Inc: Irritable Bowel Syndrome trials

The registry lists 11 Irritable Bowel Syndrome studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 3Phase 3 4Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)CompletedNCT03471728
• Special Drug Use Surveillance of Irribow in Female PatientsCompletedNCT02612649
• Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel SyndromeCompletedNCT02316899Phase 3
• A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)CompletedNCT01870895Phase 3
• A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel SyndromeCompletedNCT01736423Phase 3
• A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel SyndromeCompletedNCT01714843Phase 2
• A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female PatientsCompletedNCT01274000Phase 2
• A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male PatientsCompletedNCT01225237Phase 4
• A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel SyndromeCompletedNCT00918411Phase 4
• A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)CompletedNCT00189813Phase 2
• Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)CompletedNCT00189696Phase 3